DOI 10.1016/j.jvir.2025.08.047
Transarterial Microembolization Therapy for Chronic First Metatarsophalangeal Joint Pain: A New Minimally Invasive Approach.
Аннотация
PURPOSE: To evaluate the feasibility, safety, and preliminary effectiveness of transarterial microembolization (TAME) for refractory first metatarsophalangeal joint (MTPJ) pain in patients with inflammatory arthritis, gout, or osteoarthritis.
MATERIALS AND
METHODS
This prospective, single-center feasibility study included patients with chronic MTPJ pain refractory to maximal conservative therapy. Preprocedural radiography assessed joint space narrowing and structural changes. Under ultrasound (US) and fluoroscopic guidance, selective embolization targeting hypervascularity around the MTPJ was performed using an imipenem/cilastatin suspension. Pain severity (visual analog scale [VAS]) and weekly analgesic use were recorded at baseline and during follow-up. Twenty patients (27 feet; median age, 63 years; 4 males and 16 females) underwent TAME. The median follow-up duration was 5 months.
RESULTS
Median VAS scores decreased from 9 (range, 5-10) to 1 (range, 0-6) at final follow-up (P < .0001). Weekly analgesic use dropped from a median of 7 (range, 0-20) to 0 (range, 0-3) (P < .0001). One patient (3.7%) experienced transient skin discoloration, which resolved spontaneously. No major complications occurred.
CONCLUSIONS
Based on the results of this prospective feasibility study, TAME with imipenem/cilastatin appears to be a promising and well-tolerated technique for the treatment of chronic first MTPJ pain. Larger, long-term studies are warranted to confirm these findings.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.